Atlas Trials

A Phase 2 Study of HX301 in Patients with High-grade Giloma

Clinical trial NCT06703255 · RECRUITING

Trial details

NCT number
NCT06703255
Sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Glioma
Start date
2025-01-08
Primary completion
2026-12-31
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.